Articles by Zachary Bessette
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin has a promising efficacy and safety profile.
The FDA is granting a priority review for EV/pembro as well as nivo/chemo for the treatment of patients with la/mUC.
Drs. Woldu and Pierorazio presented on disparities in RCC care and outcomes as well as appropriate AS in small renal masses.
Dr. McKiernan provided the argument for surveillance in the event of complete clinical response after NAC for MIBC.
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
An analysis compared the outcomes of patients with mRCC who underwent cytoreductive nephrectomy and first-line TKI or IO.
Surgery for locally advanced RCC may be safe for patients after neoadjuvant durvalumab with or without tremelimumab.
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits.
Recent data suggest good quality of life outcomes for patients with muscle-invasive bladder cancer after trimodality therapy.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
A Danish study suggests that diabetes has a significant impact on OS in patients with RCC who undergo nephrectomy.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Zanzalintinib shows promising antitumor activity and manageable toxicity in patients with previously treated advanced ccRCC.
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Lenvatinib plus pembrolizumab versus pembrolizumab alone as a first-line therapy for patients with advanced UC.
Clarity Pharmaceuticals has partnered with PSI CRO AG to launch a phase 3 diagnostic trial of SAR-bisPSMA in prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.